New Deal for Obesity Drugs
The Trump administration has announced a significant agreement with pharmaceutical companies Eli Lilly and Novo Nordisk aimed at reducing the prices of their obesity medications.
According to a senior administration official, out-of-pocket expenses for these drugs could range from $50 to $350, depending on dosage and insurance coverage.
President Trump described the drug pricing agreement as an “amazing thing,” asserting that it would “save lives and improve the health of millions of Americans.” He emphasized the importance of affordable healthcare, stating, “Americans deserve the best health care in the world, and we’re now getting it at the lowest price.”
The announcement was made in the Oval Office with notable figures including Eli Lilly CEO David Ricks, Novo Nordisk CEO Mike Doutsdar, Health and Human Services Secretary Robert F. Kennedy Jr., and Medicare Administrator Mehmet Oz.
David Ricks remarked on the significance of this day as a turning point in combating chronic diseases, highlighting it as a landmark achievement for both President Trump and Secretary Kennedy.
The agreement aims to lower the initial oral dose prices of Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to approximately $149 per month. Injectable GLP-1 medications will start at around $245 monthly.
Medicare and Medicaid will cover these drugs’ costs, with drugmakers agreeing to reduce government pricing to $245 monthly. Medicare patients will face co-pays capped at $50.
The injectable medication could cost up to $1,400 monthly without insurance coverage. However, some out-of-pocket deals may allow patients to access Zepbound for $349 initially and $500 for subsequent doses. Wegovy is also priced directly at $500.
While some insurance plans may cover these drugs, many do not include them for weight-loss treatments.
Kennedy noted that this initiative supports those who have been overlooked by traditional healthcare systems due to economic barriers associated with obesity treatment.
This class of medication is primarily used for treating type 2 diabetes alongside obesity but is not typically covered by Medicare when prescribed solely for weight loss.
The drugs will soon be accessible via TrumpRX, a forthcoming website designed to offer prescription medications at government-negotiated prices. Initial pricing is expected to be set at or below $350, potentially decreasing further over time.
The Obesity Medicine Association welcomed this announcement as a crucial step toward recognizing obesity as a serious chronic disease rather than merely a lifestyle choice. They expressed eagerness to collaborate with various stakeholders to ensure effective implementation of these changes in clinical practice.
Dr. Jeffrey A. Singer from the Cato Institute shared mixed feelings regarding the announcement. While he acknowledged that lower prices could lessen taxpayer subsidies for Medicare beneficiaries, he criticized using tariffs as leverage against pharmaceutical companies.
This initiative follows Trump’s previous imposition of a 100% tariff on imported pharmaceuticals aimed at driving down costs domestically.
